
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp is positioned for sustainable revenue growth, particularly with its flagship product MACI, which is anticipated to experience a volume growth of approximately 14.8% compounded annually, driven by increasing market penetration. Additionally, the average selling prices (ASPs) for MACI are projected to rise by 300 to 500 basis points annually, further enhancing revenue potential. Overall, these factors suggest a robust outlook for MACI's top-line growth, with estimates indicating a year-over-year increase in the high teens to low twenties by fiscal year 2026.
Bears say
The outlook on Vericel Corp's stock is negatively impacted by a reduction in expected revenues from its MACI product for fiscal years 2026 and 2027, with a decrease of approximately 200 basis points projected. Potential risks further compound this negativity, as there are concerns regarding lower adoption rates for MACI Arthro, slower growth in burn care sales, and possible disruptions associated with the expansion of the sales force. Additionally, uncertainties surrounding physician adoption of MACI and MACI Arthro, variable demand for Epicel, and the possibility of delays in NexoBrid's approval contribute to broader concerns regarding the company's revenue trajectory.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares